"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 4 | 0 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 0 | 3 |
| 2004 | 5 | 0 | 5 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 2 | 5 |
| 2007 | 3 | 3 | 6 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 3 | 7 |
| 2010 | 15 | 1 | 16 |
| 2011 | 11 | 0 | 11 |
| 2012 | 9 | 0 | 9 |
| 2013 | 9 | 4 | 13 |
| 2014 | 6 | 4 | 10 |
| 2015 | 12 | 1 | 13 |
| 2016 | 5 | 0 | 5 |
| 2017 | 11 | 0 | 11 |
| 2018 | 8 | 2 | 10 |
| 2019 | 9 | 0 | 9 |
| 2020 | 5 | 0 | 5 |
| 2021 | 9 | 0 | 9 |
| 2022 | 5 | 0 | 5 |
| 2023 | 5 | 0 | 5 |
| 2024 | 7 | 0 | 7 |
| 2025 | 13 | 1 | 14 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells. Nat Cancer. 2026 Sep; 7(9):1387-1405.
-
Tumor-targeted interferon-a gene therapy for glioblastoma: a phase 1 trial. Nat Med. 2026 Jun; 32(6):2216-2226.
-
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. J Clin Oncol. 2026 Jul 20; 44(21):2048-2058.
-
Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models. J Clin Invest. 2026 May 15; 136(10).
-
Microglial fructose metabolism is essential for glioblastoma growth. Proc Natl Acad Sci U S A. 2026 Mar 24; 123(12):e2521256123.
-
Altered perivascular diffusivity in glioblastoma: integrating DTI-ALPS index with radio-pathomic and histopathologic correlates. J Neurooncol. 2026 Feb 21; 177(1).
-
Now you serine, now you don't. Trends Pharmacol Sci. 2025 11; 46(11):1047-1048.
-
Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimics. Nat Commun. 2025 Sep 29; 16(1):8341.
-
Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma. Cell Rep. 2025 10 28; 44(10):116342.
-
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 09 20; 43(27):3032-3040.